AN2 Therapeutics, Inc.·4

Feb 23, 4:29 PM ET

Readnour Robin Shane 4

4 · AN2 Therapeutics, Inc. · Filed Feb 23, 2026

Research Summary

AI-generated summary of this filing

Updated

AN2 Therapeutics (ANTX) Director Robin Readnour Receives Award

What Happened Readnour Robin Shane (Director) received a grant of 20,400 derivative shares on February 20, 2026. The filing shows an acquisition at $0.00 (no cash paid) and lists the award as a derivative security; the grant was reported on February 23, 2026. The award carries a vesting condition: the shares will vest on February 20, 2027, subject to continuous service through that date.

Key Details

  • Transaction date: 2026-02-20; Filing date: 2026-02-23 (timely filing).
  • Security type: Derivative award (code A — grant/award); price listed $0.00.
  • Amount: 20,400 shares (derivative); reported value on Form 4 is $0.
  • Vesting: Footnote — shares vest 2027-02-20 if continuous service is provided.
  • Shares owned after transaction: not disclosed in this Form 4.
  • No 10b5-1, tax-withholding, or sale activity noted in this filing.

Context This was a compensation-style grant rather than an open-market purchase or sale. Derivative awards like this (RSUs or options) typically vest over time and do not represent immediately tradeable common stock; they are commonly used to retain directors or align their interests with shareholders. Because the award vests in one year, there is no immediate change to the director’s liquid holdings reported here.

Insider Transaction Report

Form 4
Period: 2026-02-20
Transactions
  • Award

    Stock Option (Right to Buy)

    [F1]
    2026-02-20+20,40020,400 total
    Exercise: $1.04Exp: 2036-02-19Common Stock (20,400 underlying)
Footnotes (1)
  • [F1]The option shares shall vest on February 20, 2027, subject to the Reporting Person providing continuous service through such date.
Signature
/s/ Lucy Day, Attorney-in-Fact for Robin Shane Readnour|2026-02-23

Documents

1 file
  • 4
    ownership.xmlPrimary

    4